Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Harpoon Therapeutics

Evaluate

December 21, 2022

Remarkably, interest in BCMA continues

But, as Celyad bows out, how do you compete in a field as crowded as this?

December 14, 2022

Ash 2022 movers – Glycomimetics shakes off its sickle cell past

Meanwhile, there was bad blood between cell therapy players and their investors.

Article image
Vantage logo
November 04, 2022

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.

Article image
Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.

Article image
Vantage logo
June 06, 2022

Asco 2022 – the spirit of Rova-T struggles to live on

DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.

Article image
Vantage logo
May 27, 2022

Asco 2022 – great expectations for Adicet, Arcellx and PMV

Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.

Article image
Vantage logo
December 21, 2021

Sanofi moves further into next-gen oncology

Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.

Article image
Vantage logo
June 09, 2021

Asco 2021 movers – PDS wins, but big pharma reigns

PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.

Article image
Vantage logo
March 29, 2021

The world’s first multiple myeloma cell therapy has it all to do

Article image
Vantage logo
July 15, 2020

Glaxo edges towards first approval for anti-BCMA mechanism

Article image
Vantage logo
April 16, 2019

US shutdown dampens first-quarter flotations

Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up